Akero Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKRO research report →
Companywww.akerotx.com
Akero Therapeutics, Inc. , a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
- CEO
- Andrew Cheng
- IPO
- 2019
- Employees
- 69
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $4.50B
- P/E
- -15.31
- P/S
- 0.00
- P/B
- 4.68
- EV/EBITDA
- -15.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -30.68%
- ROIC
- -34.42%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-252,060,000 · -66.09%
- EPS
- $-3.75 · -29.76%
- Op Income
- $-285,423,000
- FCF YoY
- -58.98%
Performance & Tape
- 52W High
- $58.40
- 52W Low
- $21.34
- 50D MA
- $53.06
- 200D MA
- $48.19
- Beta
- -0.40
- Avg Volume
- 2.56M
Get TickerSpark's AI analysis on AKRO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 9, 25 | Heyman Tomas J. | sell | 13,000 |
| Dec 9, 25 | Heyman Tomas J. | sell | 26,000 |
| Dec 9, 25 | Heyman Tomas J. | sell | 15,000 |
| Dec 9, 25 | Heyman Tomas J. | sell | 15,000 |
| Dec 9, 25 | Heyman Tomas J. | sell | 9,398 |
| Dec 9, 25 | Xu Yuan | sell | 9,398 |
| Dec 9, 25 | Xu Yuan | sell | 15,000 |
| Dec 9, 25 | Xu Yuan | sell | 15,000 |
| Dec 9, 25 | Xu Yuan | sell | 13,000 |
| Dec 9, 25 | Xu Yuan | sell | 26,000 |
Our AKRO Coverage
We haven't published any research on AKRO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AKRO Report →